Regulatory action was based on data from the Phase III QUASAR trial, which demonstrated that Eylea HD dosed every eight weeks ...

The partners overcame an earlier rejection to win a seventh use for Dupixent, though some analysts are skeptical of its sales ...

While most students spend their January break catching up on well-deserved sleep or binge-watching Netflix, 20-year-old Ruby ...

Pharma advertisers have kicked off 2025 with a bang, with the top 10 spenders throwing almost 30% more money behind their TV ...

BRIDGEWATER, NJ, USA and BENGALURU, Karnataka, India I April 15, 2025 I Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and ...

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today a settlement and license agreement with ...

Lined up for the FDA in the coming weeks are a cell-based gene therapy for a rare skin disease and two product expansions for Regeneron, one with partner Sanofi.

Longest international trial on the effects of tirzepatide on weight in 700 adults with overweight or obesity and prediabetes reveals three distinct patterns of weight loss trajectories, with patients ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

In this article, we are going to take a look at where Regeneron Pharmaceuticals ... expanding into polygenic disorders such as diabetes. Synthetic biology is also projected to experience ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals ... cell disease and beta-thalassemia—expanding into polygenic disorders such as diabetes. Synthetic biology is also ...

PAD and Diabetes: A Particular Clinical Challenge ... Prothena Biosciences, Regeneron, Regio Biosciences, Sanofi-Aventis, Silence Therapeutics, Smith & Nephew, Stealth BioTherapeutics, VarmX ...